Global Herpes Treatment Market to Grow at a CAGR of 12.9% by 2021 - Key Vendors are Gilead, GlaxoSmithKline, Merck & Novartis - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Herpes Treatment Market 2017-2021" report to their offering.

The global herpes treatment market to grow at a CAGR of 12.97% during the period 2017-2021.

This report, Global Herpes Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion operating in this market.

The latest trend gaining momentum in the market is emergence of novel therapies. High dependency on a limited number of therapies is a major challenge being faced by the herpes treatment market. For instance, genital and oral herpes at present do not have any cure; the disease can only be managed by the available treatment options. Several studies are under trial and emergence of better therapies are expected in the coming times. The major drugs present for the treatment of genital herpes control the outbreaks of the disease but not the shedding.

According to the report, one of the major drivers for this market is increasing prevalence of herpes infection. Apart from traditional risk factors such as sexual or physical contact with the infected person, there have been several other factors contributing to the rising prevalence of herpes. People with the weaker immune system due to the intake of immunosuppressants for an organ transplant are vulnerable to herpes infection and is one of the major factors for increasing prevalence of herpes. The immunocompromised status is assumed to be more vulnerable to catch this viral infection.

Key vendors:

  • Gilead
  • GlaxoSmithKline
  • Merck
  • Novartis

Other prominent vendors:

  • Abbott
  • Agenus
  • Genocea
  • Mylan
  • Teva Pharmaceutical Industries
  • Vical

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market introduction

Part 06: Pipeline landscape

Part 07: Market segmentation by virus type

Part 08: Geographical segmentation

Part 09: Key leading count

Part 10: Drivers and challenges

Part 11: Market trends

Part 12: Vendor landscape

Part 13: Key vendor analysis

For more information about this report visit https://www.researchandmarkets.com/research/jzxtjp/global_herpes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Sexual and Reproductive Health Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Sexual and Reproductive Health Drugs